Health Economic Impact of Introducing an Adult-Focused 21-valent PCV in the Canadian Adult Population
Author(s)
Oluwaseun Sharomi, B.Sc., M.Sc., Ph.D.1, Scott Weinrich, B.Sc., M.Sc., Ph.D.1, Marie-Claude Meilleur, B.Sc., MA2, Kevin Bakker, B.Sc., M.Sc., Ph.D.1, Tufail Malik, B.Sc., M.Sc., Ph.D.1, Rachel J. Oidtman, B.Sc., M.Sc., Ph.D.1;
1Merck & Co. Inc., Rahway, NJ, USA, 2Merck Canada Inc., Kirkland, QC, Canada
1Merck & Co. Inc., Rahway, NJ, USA, 2Merck Canada Inc., Kirkland, QC, Canada
OBJECTIVES: Assess the health economic impact of the 20-valent PCV(PCV20) and 21-valent PCV(V116) in older adults in Canada.
METHODS: A dynamic transmission model was calibrated using age- and serotype-specific Canadian IPD data from 2001 to 2019. The model incorporated historical demographic data, vaccine efficacy values, and healthcare costs specific to Canada. The calibrated model was used to simulate the incidence of IPD, inpatient and outpatient non-bacteremic pneumococcal pneumonia (NBPP), and the associated healthcare costs under two vaccination scenarios: PCV20 and V116. The analysis focused on adults aged ≥15, with particular emphasis on those aged ≥65, and was conducted from both payer and societal perspectives (PP and SP) over a 100-year horizon.
RESULTS: Compared to PCV20 in adults aged ≥65 in Canada, V116 is projected to prevent 15,258 more cases of IPD. V116 is also projected to prevent more cases of post-meningitis sequelae, inpatient and outpatient NBPP, and deaths indicating that V116 is more beneficial than the PCV20. The projected cost of care for individuals infected with pneumococcal disease (PD) is approximately $86.7 billion (SP) and $75.8 billion (PP) for the V116 strategy. In comparison, the costs (2024$) for the PCV20 strategy are about $87.7 billion (SP) and $76.6 billion (PP). When factoring in the costs of the vaccination program, the overall costs of the PCV20 strategy are roughly $393 million (SP) and $286 million (PP) higher than that of the V116 strategy, suggesting the PCV20 program is expected to be more expensive than the V116 program.
CONCLUSIONS: The analysis demonstrates the benefits of adult PCV vaccination in Canada, with projections indicating V116 could substantially reduce the burden of PD while also being a cost-saving use of resources compared to PCV20 in adults ≥65 years from both the societal and payer perspective. Thus, providing a strong rationale for considering V116 in the national immunization policies.
METHODS: A dynamic transmission model was calibrated using age- and serotype-specific Canadian IPD data from 2001 to 2019. The model incorporated historical demographic data, vaccine efficacy values, and healthcare costs specific to Canada. The calibrated model was used to simulate the incidence of IPD, inpatient and outpatient non-bacteremic pneumococcal pneumonia (NBPP), and the associated healthcare costs under two vaccination scenarios: PCV20 and V116. The analysis focused on adults aged ≥15, with particular emphasis on those aged ≥65, and was conducted from both payer and societal perspectives (PP and SP) over a 100-year horizon.
RESULTS: Compared to PCV20 in adults aged ≥65 in Canada, V116 is projected to prevent 15,258 more cases of IPD. V116 is also projected to prevent more cases of post-meningitis sequelae, inpatient and outpatient NBPP, and deaths indicating that V116 is more beneficial than the PCV20. The projected cost of care for individuals infected with pneumococcal disease (PD) is approximately $86.7 billion (SP) and $75.8 billion (PP) for the V116 strategy. In comparison, the costs (2024$) for the PCV20 strategy are about $87.7 billion (SP) and $76.6 billion (PP). When factoring in the costs of the vaccination program, the overall costs of the PCV20 strategy are roughly $393 million (SP) and $286 million (PP) higher than that of the V116 strategy, suggesting the PCV20 program is expected to be more expensive than the V116 program.
CONCLUSIONS: The analysis demonstrates the benefits of adult PCV vaccination in Canada, with projections indicating V116 could substantially reduce the burden of PD while also being a cost-saving use of resources compared to PCV20 in adults ≥65 years from both the societal and payer perspective. Thus, providing a strong rationale for considering V116 in the national immunization policies.
Conference/Value in Health Info
2025-05, ISPOR 2025, Montréal, Quebec, CA
Value in Health, Volume 28, Issue S1
Code
EE394
Topic
Economic Evaluation
Disease
SDC: Respiratory-Related Disorders (Allergy, Asthma, Smoking, Other Respiratory), STA: Vaccines